Aditya Bardia, MD, MPH, discusses ongoing research with amcenestrant and palbociclib in estrogen receptor–positive, HER2-negative advanced breast cancer.
Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, and founding director of the Molecular and Precision Medicine Metastatic Breast Cancer Clinic at Massachusetts General Hospital Cancer Center, discusses ongoing research with amcenestrant (SAR439859) and palbociclib (Ibrance) in estrogen receptor–positive, HER2-negative advanced breast cancer, presented at the 2021 ASCO Annual Meeting.
The ongoing phase 3 AMEERA-5 trial (NCT04478266), which is assessing the combination vs letrozole (Femara) and palbociclib, was initiated on October 14, 2020, and has been conducted at 365 locations in 35 countries, according to Bardia. As of April 28, 2021, 218 patients have been enrolled.
When the trial completes enrollment, investigators will present the study's efficacy results including the progression-free survival data, Bardia says. The pivotal trial is examining an oral selective estrogen receptor degrader vs an aromatase inhibitor in the first-line setting. If positive, the findings could change the treatment landscape in the first-line setting, Bardia concludes.